
The antibody cocktail is being tested in four human populations. Two groups of people will receive the drug to test its effectiveness as a treatment for Covid-19; the other two will receive it as a possible prevention.
“We’ll be hopefully to quickly test the safety and then start understanding the efficacy for four major different settings of this virus challenge,” Regeneron’s chief scientific officer, Dr. George Yancopoulos, said on CNBC’s “Squawk Box.”
Learn more here (via CNBC Television)»